Bionor Pharma
- ByEdison
- •
Prepping for the future; REDUC read-out in H215Following encouraging interim data from the Phase II REDUC trial of Vacc- 4x with romidepsin, Bionor Pharma (OSLO:BIONOR) has set a...
As of December 15, 2016, Bionor Pharma ASA was acquired by Solon Eiendom AS in a reverse merger transaction. Bionor Pharma ASA, a biotechnology company, engages in the development of vaccines for viral diseases. It focuses on developing a therapeutic vaccine Vacc-4x, a human immunodeficiency virus (HIV) vaccine candidate, which is in clinical trials for reducing viral load and killing virus producing cells. The company also engages in developing Vacc-C5, a peptide designed to induce antibody responses to the HIV gp120 C5 domain; and Vacc-FLU, a preclinical phase influenza vaccine. In addition, it offers nutraceutical products, such as Nutri5 and NutriPro. The company operates in Norway, Europe, and Russia. The company was formerly known as Nutri Pharma ASA and changed its name to Bionor Pharma ASA in June 2010. Bionor Pharma ASA was founded in 1993 and is headquartered in Oslo, Norway.